Delta-Fly Pharma, Inc. (4598) Stock Price

Delta-Fly Pharma is committed to treating cancer patients comprehensively and providing treatments that patients can confidently recommend to their families. The company specializes in developing anticancer drugs, using a proprietary approach called "modular drug discovery." This method creates new anticancer drugs by utilizing existing anticancer active substances as "modules" and applying creative innovations to them.

Delta-Fly Pharma's business operations focus primarily on anticancer drug research and development. Specifically, the company is developing anticancer drug candidates including DFP-10917, DFP-14323, DFP-11207, DFP-14927, DFP-17729, and DFP-10825. Each of these compounds has a different mechanism of action and targets therapeutic effects against specific cancer types.

Among the company's pipeline, DFP-10917 targets relapsed or refractory acute myeloid leukemia, while DFP-14323 aims to improve immune function against solid tumors such as lung cancer. DFP-11207 targets gastrointestinal cancers including pancreatic cancer, and DFP-14927 features polymer-based delivery for solid tumors. DFP-17729 aims to improve the cancer microenvironment, while DFP-10825 delivers nucleic acid therapeutics for peritoneal metastatic cancer.

Delta-Fly Pharma pursues efficient research and development through effective use of external resources and partnerships with pharmaceutical companies. The company's revenue model consists of upfront payments from partner pharmaceutical companies, milestone payments, development collaboration fees, and future royalty income. This approach enables the company to generate revenue aligned with research and development progress.

Delta-Fly Pharma is committed to treating cancer patients holistically and providing treatments that patients can confidently recommend to their families. The company specializes in developing anticancer drugs, using a proprietary approach called "modular drug discovery." This method creates new anticancer drugs by utilizing existing anticancer active compounds as "modules" and applying creative modifications.

Delta-Fly Pharma's growth strategy focuses on advancing its development pipeline and establishing partnership agreements. Specifically, the company is conducting clinical trials for anticancer drug candidates such as DFP-10917 and DFP-14323, aiming for early market launch. The company also secures stable revenue streams through licensing agreements in various regions.

Delta-Fly Pharma sets revenue targets based on research and development progress and does not prioritize traditional management metrics such as ROA and ROE. Instead, the company sustains continuous R&D investment by generating upfront payments and milestone revenues from licensing agreements. This approach enables the company to expand its development pipeline and pursue new compound discovery.

Delta-Fly Pharma recognizes strengthening its financial position and securing talent as critical priorities. Given the substantial R&D costs required, the company raises capital from equity markets and financial institutions to strengthen its financial foundation. The company also leverages external recruitment firms to ensure efficient organizational operations and secure appropriate talent.